150 related articles for article (PubMed ID: 16806969)
21. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
[TBL] [Abstract][Full Text] [Related]
22. An anti-urokinase plasminogen activator receptor (uPAR) antibody: crystal structure and binding epitope.
Li Y; Parry G; Chen L; Callahan JA; Shaw DE; Meehan EJ; Mazar AP; Huang M
J Mol Biol; 2007 Jan; 365(4):1117-29. PubMed ID: 17101149
[TBL] [Abstract][Full Text] [Related]
23. An efficient system for production of recombinant urokinase-type plasminogen activator.
Tang W; Sun ZY; Pannell R; Gurewich V; Liu JN
Protein Expr Purif; 1997 Dec; 11(3):279-83. PubMed ID: 9425632
[TBL] [Abstract][Full Text] [Related]
24. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
[TBL] [Abstract][Full Text] [Related]
25. Mutagenesis at Pro309 of single-chain urokinase-type plasminogen activator alters its catalytic properties.
Sun Z; Liu JN
Proteins; 2005 Dec; 61(4):870-7. PubMed ID: 16231330
[TBL] [Abstract][Full Text] [Related]
26. [Urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in the seminal plasma and sperm of fertile and oligoasthenozoospermia males].
Wang L; Guan HT; Tian YH; Xiong CL
Zhonghua Nan Ke Xue; 2006 Sep; 12(9):791-3. PubMed ID: 17009528
[TBL] [Abstract][Full Text] [Related]
27. Recombinant production of a hybrid plasminogen activator composed of surfactant protein B and low-molecular-weight urokinase.
Ruppert C; Mahavadi P; Wygrecka M; Weaver TE; Magdolen V; Idell S; Preissner KT; Seeger W; Günther A; Markart P
Thromb Haemost; 2008 Dec; 100(6):1185-92. PubMed ID: 19132247
[TBL] [Abstract][Full Text] [Related]
28. A quantitative receptor assay using Triton X-114 for plasminogen activator binding proteins in solubilized membranes from human liver and placenta.
Nguyen G; Kruithof EK
Anal Biochem; 1993 Feb; 208(2):277-82. PubMed ID: 8383929
[TBL] [Abstract][Full Text] [Related]
29. Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator.
Ploug M; Behrendt N; Løber D; Danø K
Semin Thromb Hemost; 1991 Jul; 17(3):183-93. PubMed ID: 1665583
[No Abstract] [Full Text] [Related]
30. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
[TBL] [Abstract][Full Text] [Related]
31. Adenoviral gene transfer of a u-PA receptor-binding plasmin inhibitor and green fluorescent protein: inhibition of migration and visualization of expression.
Lamfers ML; Wijnberg MJ; Grimbergen JM; Huisman LG; Aalders MC; Cohen FN; Verheijen JH; van Hinsbergh VW; Quax PH
Thromb Haemost; 2000 Sep; 84(3):460-7. PubMed ID: 11019972
[TBL] [Abstract][Full Text] [Related]
32. Soluble urokinase receptor from fibrosarcoma HT-1080 cells.
Lau HK; Kim M
Blood Coagul Fibrinolysis; 1994 Aug; 5(4):473-8. PubMed ID: 7841301
[TBL] [Abstract][Full Text] [Related]
33. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
[TBL] [Abstract][Full Text] [Related]
34. The ovine urokinase plasminogen activator and its receptor cDNAs: molecular cloning, characterization and expression in various tissues.
Theodorou G; Bizelis I; Rogdakis E; Politis I
Gene; 2009 Aug; 443(1-2):158-69. PubMed ID: 19389465
[TBL] [Abstract][Full Text] [Related]
35. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
36. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
[TBL] [Abstract][Full Text] [Related]
37. Anthocyanidins inhibit migration of glioblastoma cells: structure-activity relationship and involvement of the plasminolytic system.
Lamy S; Lafleur R; Bédard V; Moghrabi A; Barrette S; Gingras D; Béliveau R
J Cell Biochem; 2007 Jan; 100(1):100-11. PubMed ID: 16823770
[TBL] [Abstract][Full Text] [Related]
38. High-yield expression, purification, characterization, and structure determination of tag-free Candida utilis uricase.
Liu X; Wen M; Li J; Zhai F; Ruan J; Zhang L; Li S
Appl Microbiol Biotechnol; 2011 Nov; 92(3):529-37. PubMed ID: 21573940
[TBL] [Abstract][Full Text] [Related]
39. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.
Stoppelli MP; Corti A; Soffientini A; Cassani G; Blasi F; Assoian RK
Proc Natl Acad Sci U S A; 1985 Aug; 82(15):4939-43. PubMed ID: 2991901
[TBL] [Abstract][Full Text] [Related]
40. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.
Rabbani SA; Mazar AP; Bernier SM; Haq M; Bolivar I; Henkin J; Goltzman D
J Biol Chem; 1992 Jul; 267(20):14151-6. PubMed ID: 1321137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
